
EG110A is an investigational DNA medicine under development for neurogenic detrusor overactivity with urinary incontinence.
In this video, Michael B. Chancellor, MD, discusses the background, findings and takeaways of the study, “An evaluation of women with persistent or recurrent stress urinary incontinence (SUI) following surgery in a double-bling, randomized, controlled trial comparing safety and efficacy of autologous muscle derived cells for urinary sphincter repair (AMDC-USR) with placebo (PBO),” presented at the 2021 American Urological Association Annual Meeting. Chancellor is a professor and director of neurourology at Oakland University, Royal Oak, Michigan.

